Penelope Ewbank, MD
Allergy & Immunology · Peoria, ILNPI 1558358911
Payments from drug & device makers
Across 650 payments — averaging $95.88 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$52K
- AstraZeneca$2K
- Sanofi$1K
- Takeda Pharmaceuticals U.S.A., Inc.$1K
- Regeneron Healthcare Solutions, Inc.$917
- CSL Behring$887
- plus $4K from 31 others
What the payments were for
- Consulting fees$470%
- Speaking & faculty fees$46,45075%
- Travel & lodging$2,5924%
- Food & beverage$12,91221%
- Education$3201%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 145 | $51,815 |
| AstraZeneca | 89 | $1,983 |
| Sanofi | 57 | $1,222 |
| Takeda Pharmaceuticals U.S.A., Inc. | 46 | $1,008 |
| Regeneron Healthcare Solutions, Inc. | 31 | $917 |
| CSL Behring | 46 | $887 |
| Boehringer Ingelheim | 36 | $572 |
| Pfizer | 34 | $566 |
| Genentech USA, Inc. | 18 | $364 |
| Teva Pharmaceuticals USA, Inc. | 23 | $323 |
| Grifols USA, LLC | 15 | $312 |
| Amgen(2 entities) | 15 | $308 |
| Novartis | 11 | $264 |
| Octapharma USA, Inc. | 4 | $172 |
| Phadia US Inc. | 8 | $153 |
| Optinose US, Inc. | 7 | $148 |
| Alk-abello, Inc | 8 | $136 |
| ARS Pharmaceuticals Operations, Inc. | 5 | $132 |
| Kaleo, Inc. | 7 | $126 |
| Pharming Healthcare, Inc. | 4 | $110 |
| ADMA Biomanufacturing LLC | 5 | $96 |
| Biocryst US Sales Co., LLC | 4 | $93 |
| Greer Laboratories, Inc. | 4 | $84 |
| Verona Pharma, Inc. | 4 | $81 |
| Aimmune Therapeutics, Inc. | 3 | $70 |
| Incyte Corporation | 3 | $65 |
| LEO Pharma Inc. | 3 | $62 |
| Shire North American Group Inc | 2 | $44 |
| Merck | 2 | $39 |
| Biocryst Pharmaceuticals, Inc. | 2 | $31 |
| Blueprint Medicines Corporation | 1 | $26 |
| Ionis Pharmaceuticals, Inc. | 1 | $25 |
| Nestle Healthcare Nutrition Inc. | 1 | $21 |
| Sanofi-aventis U.S. LLC | 1 | $21 |
| Sunovion Pharmaceuticals Inc. | 3 | $17 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $13 |
| Organon | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$62,322 in reported general payments places this provider in the 85th percentile of 161 allergy & immunology providers in Illinois.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| NucalaMepolizumab | 32 | $120,702 |
| TezspireTezepelumab-Ekko | 19 | $77,972 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 105 | $75,751 |
| Dupixent SyringeDupilumab | 18 | $66,084 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 55 | $34,259 |
| Arnuity ElliptaFluticasone Furoate | 54 | $18,035 |
| Spiriva RespimatTiotropium Bromide | 29 | $17,008 |
| Breo ElliptaFluticasone/Vilanterol | 32 | $16,868 |
| SymbicortBudesonide/Formoterol Fumarate | 55 | $13,392 |
| Advair HfaFluticasone Propion/Salmeterol | 26 | $9,873 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 44 | $6,547 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 36 | $6,278 |
| Pulmicort FlexhalerBudesonide | 22 | $5,944 |
| Azelastine Hcl | 137 | $4,838 |
| Epinephrine | 24 | $3,756 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKNucala, Trelegy Ellipta, Arnuity Ellipta, Breo Ellipta | $51,815 | $231,356223 claims |
| AstraZenecaTezspire, Breztri Aerosphere, Symbicort, Pulmicort Flexhaler | $1,983 | $131,567151 claims |
| Boehringer IngelheimSpiriva Respimat | $572 | $17,00829 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 161 allergy & immunology providers in Illinois.
Other allergy & immunology in Peoria
- Stephen SmartPeoria$41K
- Dareen SiriNormal$5.9M
- Giselle MosnaimChicago$2.2M
- Anju PetersChicago$2.1M
- Priya BansalSaint Charles$1.3M
- Rachna ShahMelrose Park$1M
- Melanie MakhijaChicago$402K
- Elizabeth LippnerChicago$329K
- Patrick WinShiloh$314K
- Christina CiaccioChicago$310K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.